{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T17:24:12Z","timestamp":1788456252925,"version":"build-2803163510"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T00:00:00Z","timestamp":1706572800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T00:00:00Z","timestamp":1706572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006447","name":"Universit\u00e4t Z\u00fcrich","doi-asserted-by":"publisher","award":["Walter and Gertrud Siegenthaler Fellowship"],"award-info":[{"award-number":["Walter and Gertrud Siegenthaler Fellowship"]}],"id":[{"id":"10.13039\/501100006447","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008273","name":"Novartis Foundation","doi-asserted-by":"publisher","award":["23A064"],"award-info":[{"award-number":["23A064"]}],"id":[{"id":"10.13039\/100008273","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background &amp; aims<\/jats:title>\n                <jats:p>With the increase in patients at risk of advanced liver disease due to the obesity epidemic, there will be a need for simple screening tools for advanced liver fibrosis. Soluble suppression of tumorigenicity 2 (sST2) is a serum biomarker for fibrotic processes. The aim of this study was to evaluate sST2 as marker for liver fibrosis in patients successfully treated for chronic hepatitis C.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>424 patients from the Swiss Hepatitis C Cohort Study were screened for inclusion in this post-hoc cohort study. Inclusion criteria were sustained virological response (SVR), available elastography (VCTE) and serum samples for biomarker analysis before and after treatment. For the validation of sST2, values were compared to VCTE, FIB-4 and APRI using Spearman\u2019s correlation and AUROC analyses.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Data of 164 subjects were finally analyzed. Median sST2 values slightly increased with VCTE-derived fibrosis stages and remained stable after reaching SVR within the respective fibrosis stage, suggesting that sST2 is not influenced by liver inflammation. However, correlation of sST2 pre- and post-treatment with VCTE was fair (Spearman\u2019s rho\u2009=\u20090.39 and rho\u2009=\u20090.36). The area under the curve (AUROC) for sST2 in detecting VCTE-defined F4 fibrosis (vs. F0-F3) before therapy was 0.74 (95%CI 0.65\u20130.83), and 0.67(95%CI 0.56\u20130.78) for the discrimination of F3\/F4 fibrosis vs. F0-F2. Adding sST2 to either APRI or FIB-4, respectively, increased diagnostic performance of both tests.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>sST2 can potentially identify patients with advanced fibrosis as a single serum marker and in combination with APRI and FIB-4.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12876-023-03116-4","type":"journal-article","created":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T11:02:15Z","timestamp":1706612535000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Evaluation of soluble suppression of tumorigenicity 2 (sST2) as serum marker for liver fibrosis"],"prefix":"10.1186","volume":"24","author":[{"given":"Florian F.","family":"Hildenbrand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Illi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"von Felten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Bachofner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Gawinecka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnold","family":"von Eckardstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beat","family":"M\u00fcllhaupt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim C.","family":"Mertens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sena","family":"Bl\u00fcmel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,30]]},"reference":[{"issue":"2","key":"3116_CR1","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S1499-3872(16)60185-6","volume":"16","author":"S-W Jiang","year":"2017","unstructured":"Jiang S-W, Wang P, Xiang X-G, Mo R-D, Lin L-Y, Bao S-S, Lu J, Xie Q. Serum soluble ST2 is a promising prognostic biomarker in HBV-related acute-on-chronic liver failure. Hepatob & Pancreat Diseases Int. 2017;16(2):181\u20138.","journal-title":"Hepatobiliary & Pancreatic Diseases International"},{"issue":"1","key":"3116_CR2","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.jhep.2005.10.013","volume":"44","author":"G D\u2019Amico","year":"2006","unstructured":"D\u2019Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006;44(1):217\u201331.","journal-title":"J Hepatol"},{"issue":"11","key":"3116_CR3","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.1016\/j.cgh.2020.02.044","volume":"18","author":"M Mendizabal","year":"2020","unstructured":"Mendizabal M, Pi\u00f1ero F, Ridruejo E, Herz Wolff F, Anders M, Reggiardo V, Ameigeiras B, Palazzo A, Alonso C, Schinoni MI, et al. Disease Progression in patients with Hepatitis C virus infection treated with Direct-Acting Antiviral agents. Clin Gastroenterol Hepatol Official Clin Pract J Am Gastroenterol Association. 2020;18(11):2554\u20132563e2553.","journal-title":"Clin Gastroenterol Hepatology: Official Clin Pract J Am Gastroenterological Association"},{"key":"3116_CR4","doi-asserted-by":"crossref","unstructured":"Tamaki N, Kurosaki M, Yasui Y, Mori N, Tsuji K, Hasebe C, Joko K, Akahane T, Furuta K, Kobashi H et al. Change in fibrosis 4 index as predictor of high risk of incident hepatocellular carcinoma after eradication of hepatitis C virus. Clin Infect Dis 2021.","DOI":"10.1093\/cid\/ciaa1307"},{"issue":"3","key":"3116_CR5","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","volume":"75","author":"A Berzigotti","year":"2021","unstructured":"Berzigotti A, Tsochatzis E, Boursier J, Castera L, Cazzagon N, Friedrich-Rust M, Petta S, Thiele M. EASL Clinical Practice guidelines on non-invasive tests for evaluation of liver disease severity and prognosis\u2013 2021 update. J Hepatol. 2021;75(3):659\u201389.","journal-title":"J Hepatol"},{"issue":"5","key":"3116_CR6","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018","volume":"73","author":"EASL recommendations on treatment of hepatitis C","year":"2020","unstructured":"EASL recommendations on treatment of hepatitis C. Final update of the series(\u2606). J Hepatol. 2020;73(5):1170\u2013218.","journal-title":"J Hepatol"},{"issue":"2","key":"3116_CR7","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1002\/hep.31060","volume":"71","author":"MG Ghany","year":"2020","unstructured":"Ghany MG, Morgan TR, Panel A-IHCG. Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and treating Hepatitis C virus infection. Hepatology. 2020;71(2):686\u2013721.","journal-title":"Hepatology"},{"issue":"4","key":"3116_CR8","first-page":"772","volume":"13","author":"NH Afdhal","year":"2015","unstructured":"Afdhal NH, Bacon BR, Patel K, Lawitz EJ, Gordon SC, Nelson DR, Challies TL, Nasser I, Garg J, Wei LJ, et al. Accuracy of fibroscan, compared with histology, in analysis of liver fibrosis in patients with hepatitis B or C: a United States multicenter study. Clin Gastroenterol Hepatol Official Clin Pract J Am Gastroenterol Association. 2015;13(4):772\u20139. e771-773.","journal-title":"Clin Gastroenterol Hepatol Official Clin Pract J Am Gastroenterol Association"},{"issue":"4","key":"3116_CR9","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1053\/j.gastro.2008.01.034","volume":"134","author":"M Friedrich-Rust","year":"2008","unstructured":"Friedrich-Rust M, Ong M, Martens S, Sarrazin C, Bojunga J, Zeuzem S, Herrmann E. Performance of transient Elastography for the staging of liver fibrosis: a Meta-analysis. Gastroenterology. 2008;134(4):960\u2013974e968.","journal-title":"Gastroenterology"},{"issue":"6","key":"3116_CR10","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1002\/hep.21420","volume":"44","author":"N Ganne-Carri\u00e9","year":"2006","unstructured":"Ganne-Carri\u00e9 N, Ziol M, de Ledinghen V, Douvin C, Marcellin P, Castera L, Dhumeaux D, Trinchet J-C, Beaugrand M. Accuracy of liver stiffness measurement for the diagnosis of cirrhosis in patients with chronic liver diseases. Hepatology. 2006;44(6):1511\u20137.","journal-title":"Hepatology"},{"issue":"1","key":"3116_CR11","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/hep.20506","volume":"41","author":"M Ziol","year":"2005","unstructured":"Ziol M, Handra-Luca A, Kettaneh A, Christidis C, Mal F, Kazemi F, de L\u00e9dinghen V, Marcellin P, Dhumeaux D, Trinchet J-C, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology. 2005;41(1):48\u201354.","journal-title":"Hepatology"},{"issue":"7","key":"3116_CR12","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.cgh.2016.01.009","volume":"14","author":"M Lu","year":"2016","unstructured":"Lu M, Li J, Zhang T, Rupp LB, Trudeau S, Holmberg SD, Moorman AC, Spradling PR, Teshale EH, Xu F, et al. Serum biomarkers indicate long-term reduction in liver fibrosis in patients with sustained virological response to treatment for HCV infection. Clin Gastroenterol Hepatol. 2016;14(7):1044\u20131055e1043.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"3116_CR13","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/liv.13256","volume":"37","author":"JA Bachofner","year":"2017","unstructured":"Bachofner JA, Valli PV, Kroger A, Bergamin I, Kunzler P, Baserga A, Braun D, Seifert B, Moncsek A, Fehr J, et al. Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis-4 score and aspartate aminotransferase-platelet ratio index. Liver Int. 2017;37(3):369\u201376.","journal-title":"Liver Int"},{"key":"3116_CR14","doi-asserted-by":"crossref","unstructured":"He L, Deng L, Zhang Q, Guo J, Zhou J, Song W, Yuan F. Diagnostic Value of CK-18, FGF-21, and related biomarker panel in nonalcoholic fatty liver disease: a systematic review and Meta-analysis. Biomed Res Int. 2017;2017:9729107.","DOI":"10.1155\/2017\/9729107"},{"key":"3116_CR15","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/s12879-016-1543-x","volume":"16","author":"SL Huan","year":"2016","unstructured":"Huan SL, Zhao JG, Wang ZL, Gao S, Wang K. Relevance of serum interleukin-33 and ST2 levels and the natural course of chronic hepatitis B virus infection. BMC Infect Dis. 2016;16:200.","journal-title":"BMC Infect Dis"},{"issue":"5","key":"3116_CR16","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1006\/bbrc.2001.5090","volume":"284","author":"K Kuroiwa","year":"2001","unstructured":"Kuroiwa K, Arai T, Okazaki H, Minota S, Tominaga S. Identification of human ST2 protein in the sera of patients with autoimmune diseases. Biochem Biophys Res Commun. 2001;284(5):1104\u20138.","journal-title":"Biochem Biophys Res Commun"},{"key":"3116_CR17","doi-asserted-by":"crossref","unstructured":"Oztas E, Kuzu UB, Zengin NI, Kalkan IH, Saygili F, Yildiz H, Celik HT, Akdogan M, Kilic MY, Koksal AS et al. Can serum ST2 levels be used as a marker of Fibrosis in Chronic Hepatitis B infection? 2015;94(47):e1889.","DOI":"10.1097\/MD.0000000000001889"},{"issue":"1","key":"3116_CR18","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/jpc.14488","volume":"56","author":"MM Shalby","year":"2020","unstructured":"Shalby MM, Ibrahim SA, Behairy OG, Behiry EG, Mahmoud DA. Diagnostic value of serum cytokeratin-18 in children with chronic liver disease. J Paediatr Child Health. 2020;56(1):41\u20136.","journal-title":"J Paediatr Child Health"},{"issue":"4","key":"3116_CR19","doi-asserted-by":"publisher","first-page":"331","DOI":"10.3343\/alm.2018.38.4.331","volume":"38","author":"HW Moon","year":"2018","unstructured":"Moon HW, Park M, Hur M, Kim H, Choe WH, Yun YM. Usefulness of enhanced liver fibrosis, glycosylation isomer of Mac-2 binding protein, Galectin-3, and Soluble Suppression of Tumorigenicity 2 for assessing liver fibrosis in Chronic Liver diseases. Annals of Laboratory Medicine. 2018;38(4):331\u20137.","journal-title":"Annals of Laboratory Medicine"},{"issue":"4","key":"3116_CR20","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1038\/cmi.2016.63","volume":"15","author":"Z Tan","year":"2018","unstructured":"Tan Z, Liu Q, Jiang R, Lv L, Shoto SS, Maillet I, Quesniaux V, Tang J, Zhang W, Sun B, et al. Interleukin-33 drives hepatic fibrosis through activation of hepatic stellate cells. Cell Mol Immunol. 2018;15(4):388\u201398.","journal-title":"Cell Mol Immunol"},{"key":"3116_CR21","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.3389\/fimmu.2018.02432","volume":"9","author":"OS Kotsiou","year":"2018","unstructured":"Kotsiou OS, Gourgoulianis KI, Zarogiannis SG. IL-33\/ST2 Axis in Organ Fibrosis. Front Immunol. 2018;9:2432.","journal-title":"Front Immunol"},{"issue":"4","key":"3116_CR22","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1378\/chest.124.4.1206","volume":"124","author":"S Tajima","year":"2003","unstructured":"Tajima S, Oshikawa K, Tominaga S, Sugiyama Y. The increase in serum soluble ST2 protein upon acute exacerbation of idiopathic pulmonary fibrosis. Chest. 2003;124(4):1206\u201314.","journal-title":"Chest"},{"issue":"5","key":"3116_CR23","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1161\/01.CIR.0000047274.66749.FE","volume":"107","author":"EO Weinberg","year":"2003","unstructured":"Weinberg EO, Shimpo M, Hurwitz S, Tominaga S, Rouleau JL, Lee RT. Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation. 2003;107(5):721\u20136.","journal-title":"Circulation"},{"issue":"6b","key":"3116_CR24","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1111\/j.1582-4934.2009.00801.x","volume":"14","author":"P Marvie","year":"2010","unstructured":"Marvie P, Lisbonne M, L\u2019Helgoualc\u2019h A, Rauch M, Turlin B, Preisser L, Bourd-Boittin K, Th\u00e9ret N, Gascan H, Piquet-Pellorce C, et al. Interleukin-33 overexpression is associated with liver fibrosis in mice and humans. J Cell Mol Med. 2010;14(6b):1726\u201339.","journal-title":"J Cell Mol Med"},{"issue":"5","key":"3116_CR25","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1006\/bbrc.2001.5306","volume":"285","author":"K Tago","year":"2001","unstructured":"Tago K, Noda T, Hayakawa M, Iwahana H, Yanagisawa K, Yashiro T, Tominaga S. Tissue distribution and subcellular localization of a variant form of the human ST2 gene product, ST2V. Biochem Biophys Res Commun. 2001;285(5):1377\u201383.","journal-title":"Biochem Biophys Res Commun"},{"key":"3116_CR26","doi-asserted-by":"publisher","first-page":"819636","DOI":"10.1155\/2012\/819636","volume":"2012","author":"J Wang","year":"2012","unstructured":"Wang J, Zhao P, Guo H, Sun X, Jiang Z, Xu L, Feng J, Niu J, Jiang Y. Serum IL-33 levels are associated with liver damage in patients with chronic hepatitis C. Mediators Inflamm. 2012;2012:819636.","journal-title":"Mediators Inflamm"},{"issue":"3","key":"3116_CR27","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1111\/j.1365-2893.2005.00594.x","volume":"12","author":"B Kronenberger","year":"2005","unstructured":"Kronenberger B, Wagner M, Herrmann E, Mihm U, Piiper A, Sarrazin C, Zeuzem S. Apoptotic cytokeratin 18 neoepitopes in serum of patients with chronic hepatitis C. J Viral Hepat. 2005;12(3):307\u201314.","journal-title":"J Viral Hepat"},{"issue":"1","key":"3116_CR28","doi-asserted-by":"publisher","first-page":"97","DOI":"10.4049\/jimmunol.1501175","volume":"196","author":"M Rau","year":"2016","unstructured":"Rau M, Schilling A-K, Meertens J, Hering I, Weiss J, Jurowich C, Kudlich T, Hermanns HM, Bantel H, Beyersdorf N, et al. Progression from nonalcoholic fatty liver to nonalcoholic steatohepatitis is marked by a higher frequency of Th17 cells in the liver and an Increased Th17\/Resting Regulatory T Cell Ratio in Peripheral Blood and in the liver. J Immunol. 2016;196(1):97\u2013105.","journal-title":"J Immunol"},{"issue":"12","key":"3116_CR29","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1111\/j.1365-2893.2009.01251.x","volume":"17","author":"C Sgier","year":"2010","unstructured":"Sgier C, Mullhaupt B, Gerlach T, Moradpour D, Negro F, Male PJ, Heim MH, Malinverni R, Cerny A, Dufour JF. Effect of antiviral therapy on circulating cytokeratin-18 fragments in patients with chronic hepatitis C. J Viral Hepat. 2010;17(12):845\u201350.","journal-title":"J Viral Hepat"},{"issue":"1","key":"3116_CR30","doi-asserted-by":"publisher","first-page":"101761","DOI":"10.1016\/j.clinre.2021.101761","volume":"46","author":"J Boursier","year":"2022","unstructured":"Boursier J, Decraecker M, Bourliere M, Bureau C, Ganne-Carrie N, de Ledinghen V. Quality criteria for the measurement of liver stiffness. Clin Res Hepatol Gastroenterol. 2022;46(1):101761.","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"2","key":"3116_CR31","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1053\/jhep.2003.50346","volume":"38","author":"CT Wai","year":"2003","unstructured":"Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, Lok AS. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38(2):518\u201326.","journal-title":"Hepatology"},{"issue":"6","key":"3116_CR32","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1002\/hep.21178","volume":"43","author":"RK Sterling","year":"2006","unstructured":"Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, Sulkowski S, Torriani M, Dieterich FJ, Thomas DT. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection. Hepatology. 2006;43(6):1317\u201325.","journal-title":"Hepatology"},{"issue":"1","key":"3116_CR33","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1586\/erm.12.128","volume":"13","author":"T Mueller","year":"2013","unstructured":"Mueller T, Dieplinger B. The Presage\u00ae ST2 assay: analytical considerations and clinical applications for a high-sensitivity assay for measurement of soluble ST2. Expert Rev Mol Diagn. 2013;13(1):13\u201330.","journal-title":"Expert Rev Mol Diagn"},{"key":"3116_CR34","unstructured":"Presage ST2 test. [https:\/\/www.lifebiomedical.com\/presage-st2-test.html]."},{"key":"3116_CR35","doi-asserted-by":"publisher","first-page":"5314213","DOI":"10.1155\/2017\/5314213","volume":"2017","author":"Z Sun","year":"2017","unstructured":"Sun Z, Chang B, Gao M, Zhang J, Zou Z. IL-33-ST2 Axis in Liver Disease: progression and challenge. Mediators Inflamm. 2017;2017:5314213.","journal-title":"Mediators Inflamm"},{"issue":"4","key":"3116_CR36","first-page":"1105","volume":"18","author":"SA Ismail","year":"2017","unstructured":"Ismail SA, El Saadany S, Ziada DH, Zakaria SS, Mayah WW, Elashry H, Arafa M, Elmashad N. Cytokeratin-18 in diagnosis of HCC in patients with liver cirrhosis. Asian Pac J cancer Prevention: APJCP. 2017;18(4):1105\u201311.","journal-title":"Asian Pac J cancer Prevention: APJCP"},{"issue":"3","key":"3116_CR37","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S1386-6346(02)00277-2","volume":"25","author":"M Murota","year":"2003","unstructured":"Murota M, Watanabe S, Fujita J, Ohtsuki Y, Wu F, Yoshida S, Kita Y, Funakoshi F, Masaki T, Kurokohchi K, et al. Aberrant cytokeratin expression and high susceptibility to apoptosis in autoimmune hepatitis. Hepatol Research: Official J Japan Soc Hepatol. 2003;25(3):271\u201380.","journal-title":"Hepatol Research: Official J Japan Soc Hepatol"},{"issue":"4","key":"3116_CR38","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1111\/j.1365-2893.2011.01546.x","volume":"19","author":"AB Jazwinski","year":"2012","unstructured":"Jazwinski AB, Thompson AJ, Clark PJ, Naggie S, Tillmann HL, Patel K. Elevated serum CK18 levels in chronic hepatitis C patients are associated with advanced fibrosis but not steatosis. J Viral Hepat. 2012;19(4):278\u201382.","journal-title":"J Viral Hepat"},{"issue":"2","key":"3116_CR39","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1053\/j.gastro.2004.11.018","volume":"128","author":"L Cast\u00e9ra","year":"2005","unstructured":"Cast\u00e9ra L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, Darriet M, Couzigou P, De L\u00e9dinghen V. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology. 2005;128(2):343\u201350.","journal-title":"Gastroenterology"},{"issue":"2","key":"3116_CR40","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.jceh.2019.09.001","volume":"10","author":"RJ Wong","year":"2020","unstructured":"Wong RJ, Jain MK, Therapondos G, Shiffman ML, Kshirsagar O, Clark C, Thamer M. Sustained improvements in markers of Liver Disease Severity after Hepatitis C treatment. J Clin Exp Hepatol. 2020;10(2):114\u201323.","journal-title":"J Clin Exp Hepatol"},{"issue":"1","key":"3116_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jhep.2008.10.014","volume":"50","author":"P Bedossa","year":"2009","unstructured":"Bedossa P, Carrat F. Liver biopsy: the best, not the gold standard. J Hepatol. 2009;50(1):1\u20133.","journal-title":"J Hepatol"},{"issue":"1","key":"3116_CR42","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jhep.2008.07.039","volume":"50","author":"SH Mehta","year":"2009","unstructured":"Mehta SH, Lau B, Afdhal NH, Thomas DL. Exceeding the limits of liver histology markers. J Hepatol. 2009;50(1):36\u201341.","journal-title":"J Hepatol"},{"issue":"12","key":"3116_CR43","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1016\/j.cgh.2014.04.037","volume":"12","author":"K Patel","year":"2014","unstructured":"Patel K, Remlinger KS, Walker TG, Leitner P, Lucas JE, Gardner SD, McHutchison JG, Irving W, Guha IN. Multiplex protein analysis to determine fibrosis stage and progression in patients with chronic hepatitis C. Clin Gastroenterol Hepatology: Official Clin Pract J Am Gastroenterological Association. 2014;12(12):2113\u20132120e2111.","journal-title":"Clin Gastroenterol Hepatology: Official Clin Pract J Am Gastroenterological Association"},{"issue":"2","key":"3116_CR44","doi-asserted-by":"publisher","first-page":"100067","DOI":"10.1016\/j.jhepr.2020.100067","volume":"2","author":"K Patel","year":"2020","unstructured":"Patel K, Sebastiani G. Limitations of non-invasive tests for assessment of liver fibrosis. JHEP Rep. 2020;2(2):100067.","journal-title":"JHEP Rep"},{"key":"3116_CR45","doi-asserted-by":"crossref","unstructured":"Cardoso AC, Figueiredo-Mendes C, Villela-Nogueira CA, Marcellin P. Staging fibrosis in chronic viral Hepatitis. Viruses 2022, 14(4).","DOI":"10.3390\/v14040660"},{"key":"3116_CR46","unstructured":"Bhattacharya D, Aronsohn A, Price J, Lo Re V, Hepatitis C. Guidance 2023 Update: AASLD-IDSA recommendations for Testing, Managing, and treating Hepatitis C virus infection. Clin Infect Dis 2023."},{"issue":"3","key":"3116_CR47","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.clinbiochem.2015.07.019","volume":"49","author":"MG Neuman","year":"2016","unstructured":"Neuman MG, Cohen LB, Nanau RM. Hyaluronic acid as a non-invasive biomarker of liver fibrosis. Clin Biochem. 2016;49(3):302\u201315.","journal-title":"Clin Biochem"},{"issue":"2","key":"3116_CR48","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ajg.2017.05.005","volume":"18","author":"MA El Serafy","year":"2017","unstructured":"El Serafy MA, Kassem AM, Omar H, Mahfouz MS, El Said El Raziky M. APRI test and hyaluronic acid as non-invasive diagnostic tools for post HCV liver fibrosis: systematic review and meta-analysis. Arab J Gastroenterol. 2017;18(2):51\u20137.","journal-title":"Arab J Gastroenterol"},{"issue":"1","key":"3116_CR49","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1111\/j.1365-2036.2010.04500.x","volume":"33","author":"SM Martinez","year":"2011","unstructured":"Martinez SM, Fern\u00e1ndez-Varo G, Gonz\u00e1lez P, Sampson E, Bruguera M, Navasa M, Jim\u00e9nez W, S\u00e1nchez-Tapias JM, Forns X. Assessment of liver fibrosis before and after antiviral therapy by different serum marker panels in patients with chronic hepatitis C. Aliment Pharmacol Ther. 2011;33(1):138\u201348.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"3116_CR50","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1136\/gut.21.1.63","volume":"21","author":"E Hahn","year":"1980","unstructured":"Hahn E, Wick G, Pencev D, Timpl R. Distribution of basement membrane proteins in normal and fibrotic human liver: collagen type IV, laminin, and fibronectin. Gut. 1980;21(1):63\u201371.","journal-title":"Gut"},{"issue":"9","key":"3116_CR51","doi-asserted-by":"publisher","first-page":"e0257166","DOI":"10.1371\/journal.pone.0257166","volume":"16","author":"M Atsukawa","year":"2021","unstructured":"Atsukawa M, Tsubota A, Kondo C, Uchida-Kobayashi S, Takaguchi K, Tsutsui A, Nozaki A, Chuma M, Hidaka I, Ishikawa T, et al. A novel noninvasive formula for predicting cirrhosis in patients with chronic hepatitis C. PLoS ONE. 2021;16(9):e0257166.","journal-title":"PLoS ONE"},{"issue":"10","key":"3116_CR52","doi-asserted-by":"publisher","first-page":"e0276925","DOI":"10.1371\/journal.pone.0276925","volume":"17","author":"K Yamataka","year":"2022","unstructured":"Yamataka K, Chu PS, Koda Y, Taniki N, Morikawa R, Yoshida A, Noguchi F, Kasuga R, Tabuchi T, Ebinuma H, et al. Dynamics of type IV collagen 7S fragment on eradication of HCV with direct antiviral agents: prognostic and metabolomic impacts. PLoS ONE. 2022;17(10):e0276925.","journal-title":"PLoS ONE"},{"key":"3116_CR53","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.cca.2020.04.011","volume":"507","author":"E Homsak","year":"2020","unstructured":"Homsak E, Gruson D. Soluble ST2: a complex and diverse role in several diseases. Clin Chim Acta. 2020;507:75\u201387.","journal-title":"Clin Chim Acta"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-023-03116-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-023-03116-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-023-03116-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T12:10:16Z","timestamp":1706616616000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-023-03116-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,30]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3116"],"URL":"https:\/\/doi.org\/10.1186\/s12876-023-03116-4","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,30]]},"assertion":[{"value":"5 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patients provided written informed consent for the inclusion into SCCS (KEK ZH number EK-695). The study protocol for the presented study was in accordance with the ethical guidelines of the Declaration of Helsinki and was approved by the ethics committee of the Canton of Zurich (BASEC number 2016\u2009\u2212\u200900341).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"ELISA kits for sST2 measurements were provided by Ruwag Diagnostics, Bettlach, Switzerland. The company was neither involved in data analyses nor in the preparation and review of the manuscript. No other conflicts of interest exist for any of the authors related to this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"54"}}